Table 3.
Vancomycin exposure in patients who had therapeutic drug monitoring and the MIPD CDS tool was used.
| Neonate Platform | Child Platform | |||||
|---|---|---|---|---|---|---|
| TDM #1 | TDM #2 | TDM #3 | TDM #1 | TDM #2 | TDM #3 | |
| AUC24,ss (mgxh/L) | 433 (362–525) | 426 (367–523) | 428 (353–32) | 406 (308–530) | 421 (318–548) | 451 (338–579) |
| Cumulative Achievement of AUC24,ss/MIC >400 (%)a | 63.4% | 78.0% | 78.0% | 46.7% | 64.1% | 70.1% |
| Trough,ss (mg/L) | 9.2 (6.7-13.0) |
9.3 (7.0-13.7) |
8.5 (7.0-12.0) |
8.8 (5.5-13.2) |
9.3 (5.6-13.8) |
10.4 (6.4-15.3) |
| Cumulative Achievement of Trough,ss 5 to 20 mg/L (%)b | 78.0% | 87.8% | 90.2% | 60.5% | 79.0% | 82.6% |
| Cumulative Achievement of Trough,ss 10 to 20 mg/L (%)c | 41.5% | 53.7% | 56.1% | 28.1% | 44.3% | 47.3% |
AUC24,ss/MIC, 24-h AUC over the MIC at steady-state assuming MIC = 1 mg/L; Troughss, predicted trough concentration at steady-state; TDM #1 represents predicted exposures before any dose adjustments; TDM #2 represents predicted exposures after the first dose adjustment; TDM #3 represents predicted exposures after the second dose adjustment.
Cumulative percentage of patients who achieved AUC24,ss/MIC >400 over the first three TDM evaluations.
Cumulative percentage of patients who achieved a predicted trough of 5 to 20 mg/L over the first three TDM evaluations.
Cumulative percentage of patients who achieved a predicted trough of 10 to 20 mg/L over the first three TDM evaluations.